Previous Close | 2.5500 |
Open | 4.9100 |
Bid | 4.5000 |
Ask | 4.8000 |
Strike | 105.00 |
Expire Date | 2024-06-21 |
Day's Range | 4.8900 - 4.9300 |
Contract Range | N/A |
Volume | |
Open Interest | 80 |
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN
Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In many kidney diseases, pro
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.